Chemotherapy Induced Peripheral Neuropathy (CIPN): Clinical Translation and Symptom Management in Chemotherapy Induced Peripheral Neuropathy
14m 54s
Associate Professor Jennifer Goetner discusses key challenges and advancements in clinical trial design for chemotherapy-induced peripheral neuropathy (CIPN). She emphasizes that patient-reported outcomes, such as the CIPN 20 or FACT, are more reliable and clinically relevant than clinician-rated measures, though they may lack specificity. A clinically meaningful change in CIPN is best defined by neuropathy grades, which simplify trial design and power calculations. However, composite measures often include non-neuropathy-specific items, leading to potential misinterpretation. Goetner stresses that trial outcomes must align with the specific symptom being targeted—using broad measures for pain-focused treatments, for instance, may be inappropriate. Biomarkers offer value in early-phase trials as surrogates for disease modification, but patient-reported outcomes remain essential for proving clinical efficacy. She highlights the importance of personalizing outcomes to individual patient needs, such as loss of walking ability or hand coordination, to better reflect real-world impact. Additionally, tools that enable patients to track symptoms and trigger timely clinical contact improve communication during chemotherapy. Future research should prioritize personalized treatment strategies based on distinct CIPN subtypes, enhancing both trial design and clinical translation. These insights underscore the need for more targeted, patient-centered approaches to CIPN management.
[MUSIC]
Welcome to the peripheral nerve podcast, the official podcast of the peripheral nerve society.
Exploring topics in peripheral nerve disorders, awareness, education, and advocacy.
We are your host, Professor Sizana Park from the University of Sydney, Australia,
and Dr. Paola Alberti from University of Milano-Bicocca, Italy.
We are delighted to bring you another episode in the periphery from that Postgres series,
understanding chemotherapy induced periphery from neuropathy.
In this episode, we're so excited to welcome Associate Professor Jennifer Goetner.
Associate Professor Goetner is a leading clinical researcher in pain,
neuropathy, and clinical trial methodology at the University of Rochester.
And the principal investigator of the University of Rochester,
clinical hub of the National Institute of Health sponsored,
early phase pain investigation clinical network.
Associate Professor Goetner's walk focuses on optimizing clinical trial design
with a strong focus on peripheral neuropathy and pain.
She's experienced it as a leading investigator for multiple clinical trials of symptom
management approaches for chemotherapy induced neuropathy and other conditions.
A walk has lead to improvements in how we design and measure symptom impact in clinical trials.
For chronic pain.
Today, we will discuss the clinical translation of symptom management approaches
in CIPN and what further work needs to be done to optimize clinical trial design.
We are honored to have you here speaking with us today.
And I welcome Jennifer. It's so wonderful to have you here with us today.
Thank you for inviting me. I'm excited to be here.
I would like to start this conversation with this first question.
I was wondering if you could provide us with a brief overview of outcome measure
which quantifies CIPN and discuss how we define a clinically meaningful change in CIPN severity.
And if there are any methodological pitfalls, you would like to highlight for us.
Sure, I guess I would say for CIPN, there are different types of measures that's important
to point out. So there are measures that are patient reported that include various
symptoms and physical limitations. Good examples of those would be things like the fact
taxing and the ERTCCIPN 20. Then there are clinician rated outcomes, which are standardized
exam based measures that test more signs of peripheral neuropathy. And then there's the CTCAE,
which has both a patient reported version and a clinician reported version.
And so all of these measures have some benefit, some positives and some negatives.
The CIPN 20 and the fact are a little bit more, what I would say, as quantitative and they've
been shown to be more reproducible, more potentially more valid than the clinician reported at CTCE.
However, when it comes to what is a clinically meaningful change, I think it's easier to wrap
your head around the idea of grade one, grade two, grade three neuropathy. And that's something that
I think a lot of clinicians understand. And if you're asking me, how do I power a clinical trial?
It'd be a lot easier for me to think about, okay, let's try to aim for decreasing the number of
people who get a grade three neuropathy or a grade two neuropathy. Whereas if we're trying to think
about what's a clinically relevant difference between groups, because really that's what we're
measuring in a clinical trial, and one of these more continuous outcome measures, that's a very,
that's a much more challenging question to answer. And thank you. I think that's good. Are there any
from the perspective of clinical trial design? Are there any other methodological issues in terms
of these outcome measures that you'd like to highlight? Yeah. So I think it's the one methodological
issue to consider between the patient reported outcome measures and the clinician reported outcome
measures. So like, for example, the TNS or something like that is what is the most important thing
to measure in a clinical trial? And I think if you were thinking about a symptom management,
especially at least in the U.S. for an FDA perspective, that should always be a patient reported
outcome measure. But if we're thinking about the prevention or the prevention of neuropathy or the
chain disease modification of neuropathy, something that happens earlier before they're the symptoms
are moderate to severe, then in that case, I think it's important to think about potentially using
more of a clinician rated outcome measure. Because those measures might be able to detect neuropathy
that's not yet symptomatic. So earlier and see smaller changes that in the span of a clinical trial
could potentially have a much larger effect down the line from a disease modification or prevention
perspective. One thing, obviously, that's always challenging when you use any kind of composite
outcome measure is making sure that all of the items within that measure are relevant for the
condition. And I think one thing we found when using these measures is that they do have some
items that, yes, are important in neuropathy. And they were developed. A lot of these measures
were really developed well with input from both patients and clinicians. The challenges,
some of the things in these measures are fairly non-specific to neuropathy. And so you could
potentially improve neuropathy, but maybe not improve weakness, for example, that people might
interpret as fatigue, rather than weakness in the muscles from neuropathy. And so I think it's
important for us to examine what exactly is included in these composite measures. Is it something
that might be misinterpreted by patients or are all the items really useful? And you'll see this
reflected in what's done in the science. So for example, the CIPN 20 has 20 different items,
some of which I think are potentially not super specific to neuropathy. And so what you'll see
is a lot of times people will use just that sensory subscale because it's really just the neuropathic
sensory symptoms that it rates. And that's one way that people have gone about trying to take some
of these standardized measures and maybe making them a little bit more specific to neuropathy.
So I would say that's one of the pitfalls that I think about when I think about measuring neuropathy.
The other thing to think about is in a clinical trial is always matching your outcome with what
you hope to improve. And so the easiest example of this and the one that comes to mind for me because
of the work that I do is even though I'm studying patients with CIPN who have actually all of these
symptoms, if I'm setting a drug that helps pain, it doesn't make sense for the outcome to be this
composite measure of all different things. If the only thing I think my treatment's going to help
is pay. And so I think that's something that's also important. Even though these composite measures
are very relevant to all the different things that people experience, we also have to think about
what's the right measure for the intervention we're using. Thank you so much. I guess a little bit
more on that topic. How do you balance between outcome measures which prioritize these different
elements? So you've mentioned clinician reported evaluation or patient reported measures,
but I guess how do you also bring in emerging objective biomarker data and combine those outcome
measures? And are there any other disease groups that you've worked with that have explored these
kind of outcome measures? Yeah, so I think that we are there yet in pain or peripheral neuropathy,
necessarily to be using outcome measures as an outcome in an efficacy clinical trial.
So I am of the opinion that efficacy clinical trials always the outcome should be for a symptomatic
trial, the patient's report of that symptom. With that said, places that biomarkers can be super
helpful are in earlier stage developments, which in the FDA they call this a surrogate outcome.
So for example, if you're looking if you're investigating a disease modifying treatment of neuropathy
and you show, oh, when I do this, when I give people this treatment, the the interviewer will
learn fiber density doesn't decrease as much over time as it does with a control. And therefore,
likely if we did a larger study, we'd be able to detect a different difference in their symptoms.
But using that as an efficacy outcome to say that this treatment works clinically, to me,
I don't think that's something that I wouldn't do if I were designing a study.
The other place that I think these biomarkers can be really useful and really interesting
in things that I'm doing research in my own in my own research in pain specifically,
is looking to see if some of these biomarkers can tell us a little bit more about the neuropathy
and therefore predict which treatments might be best, which interventions might be best for
specific people. And the reason that's important is because we call people with we say people have
chemotherapy use peripheral neuropathy, but that is not a homogenous group of symptoms inside.
Some people have numbness and tingling, some people have pain, some people have large fiber
damage, some people have small fiber damage, some people have both. And so understanding better,
be able to better phenotype or characterize and using biomarkers, the type of neuropathy that people
might have in the future can help us better predict who might do best with which treatments.
Thank you. What opportunities do you think are there for clinical translation of these research
findings in the short term to improve the management of CIPN? So I think both on the therapy side,
but potentially also in terms of outcome measures and how these might be able to be applied
to routine clinical use. Yeah, so let me start with the treatments. As a clinical trialist,
I'm very hesitant to ever say, oh, give this a try if there isn't really good evidence for its
efficacy. I think as far as drugs go, I think I see a lot of people when I'm recruiting for clinical
trials who haven't tried deloxeting for their CIPN. And this is the one drug that really there is
a fairly large clinical trial demonstrating some efficacy.
And of course, the things that are prescribed for CIPN by people if you went to a neuro-alcoholic
clinic or you went to a pain specialist, they would offer that you'd drive a gablin or
duoxetine or these kind of neuropathic pain drugs because unfortunately that's all we have
right now.
And I see a lot of people who come to get assessed for clinical trials and have not yet
tried them or haven't even had them suggested them by their doctor.
And so I think potentially better educating the population.
I think the foundation of peripheral neuropathy and some other acrotic pain advocacy groups
educating patients on what they should be asking their doctors for to help them make sure
their doctors are offering them all the things that we at least do have that they can be
tried right now is really important.
One thing that I think is also interesting and this is a study that Noah Colbe is doing
right now is this idea of having people track their symptoms and whether that's a very
simple outcome of just let us know are you having XYZ symptom or some kind of more quantitative
outcome measure like the CIPN 20 or one of these other patient-ported outcome measures.
And if they get to a certain level of symptoms it's triggered that a nurse practitioner should
call them and talked to them about their symptoms.
And so it formalizes the communication between the clinical staff and the patients.
And I think that's really important because I think a lot of times patients during while
they're getting their chemo they don't really want to talk about side effects they want
in their clinic visit they want to focus on their cancer treatment they don't want to
decrease their dosage because they want to get better and they don't want to risk anything.
And so having this clear communication that you are as the patient are in the driver's
seat you get to decide about dose reductions but we need to know these things because maybe
there's other ways we can better help you and so his studies and over yet it's almost
over but I think it's going to be really interesting to see whether even though we have imperfect
tools we don't really have a lot of things that are technically proven to work quote unquote
in face three clinical trials if just having better communication between the doctors and
the patients improve the overall outcomes in terms of either CIPN or how that CIPN affects
people's lives I think it's going to be super interesting and really help inform clinical
practice.
Thank you so much for this detailed overview I was wondering if you could give your point
view on which is in your opinion that must promise an avenue for future research in CIPN
field.
Well obviously there are a lot of pharmacologic interventions that have been shown in the
preclinical space to to help with CIPN whether it's symptomatic or prevention and I think
just getting more funding dollars and more people interested in doing clinical trials
and translating those results is going to be important obviously the more trials we do
the more we'll hopefully identify things that can work for people.
One thing that I'm really interested right now is in the safe space of what we've been
talking about is outcomes I'm interested in personalizing outcomes I mentioned the different
types of validated accepted outcome measures but something I'm doing in my own work these
days is trying to personalize the outcome measures for the individual person and as I
mentioned because there's a lot of heterogeneity among the symptoms and signs that present
with CIPN as well as the things that are interfered with in a patient's life so one patient their
feet might hurt so they might not be able to go for a walk and they really like to go
for a walk and that's what they wish to get better and then another patient they might
be a violinist and their loss of their coordination their hands is really a lot of others than
the most and so I'm trying to figure out how we can personalize outcome measures so have
a primary outcome that is really what is most important to the patient or what is most
relevant to the particular patient in the trial and so that's something that I'm really
excited about right now in research in the peripheral neuropathy area and then of
course all the same things you brought up the more we can better characterize different
subtypes of CIPN and figure out how we can match the types of interventions we have to
those types of substantial subtypes of CIPN is going to hopefully help us accelerate development
of nutrients for people living with these conditions so I say those would be the places
that if I were trying to decide where to put my efforts those would be the place I'd
focus on.
Thank you so much associate professor Goentner for sharing these insights today you can
find relevant papers in the show notes and visit www.pnssi.com for more information about
the peripheral neuropathy area thank you so much for listening see you next month.
The primary purpose of the peripheral neuropathy podcast is to meet the educational needs of
its listeners and address practice gaps by providing practice oriented and scientifically
based education that will maintain an advanced competence and performance in the peripheral
nerve field.
A diversity of opinions exists in the medical field and the views of the podcast faculty
do not represent those of the peripheral nerve society or constitute an endorsement by
the peripheral nerve society.
Podcast Summary
Key Points:
Patient-reported outcomes like the CIPN 20 and FACT are more reproducible and quantitative than clinician-rated measures, but have limitations in specificity to neuropathy.
Clinically meaningful change in CIPN severity is best defined by grading (e.g., grade 1–3), especially for trial power, though continuous measures are harder to interpret.
Composite outcome measures may include non-specific items, leading to misinterpretation of symptoms like fatigue as weakness, reducing their validity.
For symptom-specific treatments, outcome measures should align closely with the targeted symptom—using broader measures risks misalignment with therapeutic goals.
Biomarkers can serve as surrogate endpoints in early-stage trials to detect disease modification, though patient-reported outcomes remain the gold standard for clinical efficacy.
Personalizing outcome measures to individual patient priorities (e.g., walking ability vs. hand coordination) improves relevance and clinical translation.
Better patient-physician communication through symptom tracking tools may improve CIPN management even without proven treatments.
Future research should focus on personalizing interventions based on neuropathy subtypes to match treatments to patient-specific symptom profiles.
Summary:
Associate Professor Jennifer Goetner discusses key challenges and advancements in clinical trial design for chemotherapy-induced peripheral neuropathy (CIPN). She emphasizes that patient-reported outcomes, such as the CIPN 20 or FACT, are more reliable and clinically relevant than clinician-rated measures, though they may lack specificity. A clinically meaningful change in CIPN is best defined by neuropathy grades, which simplify trial design and power calculations.
However, composite measures often include non-neuropathy-specific items, leading to potential misinterpretation. Goetner stresses that trial outcomes must align with the specific symptom being targeted—using broad measures for pain-focused treatments, for instance, may be inappropriate. Biomarkers offer value in early-phase trials as surrogates for disease modification, but patient-reported outcomes remain essential for proving clinical efficacy.
She highlights the importance of personalizing outcomes to individual patient needs, such as loss of walking ability or hand coordination, to better reflect real-world impact. Additionally, tools that enable patients to track symptoms and trigger timely clinical contact improve communication during chemotherapy. Future research should prioritize personalized treatment strategies based on distinct CIPN subtypes, enhancing both trial design and clinical translation.
These insights underscore the need for more targeted, patient-centered approaches to CIPN management.
FAQs
Outcome measures include patient-reported tools like the CIPN 20 and FACT, clinician-rated exams such as the CTCAE, and composite measures. Patient-reported measures are often more reproducible and sensitive to changes in symptoms than clinician-rated ones.
Clinically meaningful changes are often defined by reductions in neuropathy grades (e.g., from grade 2 to grade 1), which are easier to interpret and use in trial design than continuous symptom score differences.
They can detect subtle, pre-symptomatic neuropathy and may be more effective in identifying disease modification or prevention, especially when neuropathy is not yet symptomatic.
Some composite measures include non-specific items (like fatigue) that may be misinterpreted as neuropathy-related symptoms, potentially reducing the specificity and accuracy of the assessment.
Yes, especially in trials focused on symptom management, as patient-reported outcomes reflect the actual impact of neuropathy on daily life and are aligned with regulatory standards like those of the FDA.
Biomarkers can serve as surrogate endpoints in early development to track neuropathy progression, and help predict which patients may respond best to specific treatments by identifying subtypes of neuropathy.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.